Last reviewed · How we verify
trofosfamide, idarubicin, etoposide
Trofosfamide is an alkylating agent that interferes with DNA replication, idarubicin is an anthracycline antibiotic that intercalates DNA, and etoposide is a topoisomerase inhibitor that prevents DNA replication.
Trofosfamide is an alkylating agent that interferes with DNA replication, idarubicin is an anthracycline antibiotic that intercalates DNA, and etoposide is a topoisomerase inhibitor that prevents DNA replication. Used for Acute myeloid leukemia, Small cell lung cancer.
At a glance
| Generic name | trofosfamide, idarubicin, etoposide |
|---|---|
| Sponsor | University Hospital Tuebingen |
| Drug class | alkylating agent, anthracycline antibiotic, topoisomerase inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Trofosfamide works by attaching an alkyl group to the DNA molecule, which interferes with DNA replication and transcription. Idarubicin intercalates DNA, which prevents the replication of DNA and ultimately leads to cell death. Etoposide inhibits topoisomerase II, an enzyme that unwinds DNA during replication, which prevents DNA replication and leads to cell death.
Approved indications
- Acute myeloid leukemia
- Small cell lung cancer
Common side effects
- Myelosuppression
- Nausea and vomiting
- Hair loss
- Fatigue
- Infection
Key clinical trials
- Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |